scholarly journals ???Anatomic??? Right Hepatic Trisectionectomy (Extended Right Hepatectomy) With Caudate Lobectomy for Hilar Cholangiocarcinoma

2006 ◽  
Vol 243 (1) ◽  
pp. 28-32 ◽  
Author(s):  
Masato Nagino ◽  
Junichi Kamiya ◽  
Toshiyuki Arai ◽  
Hideki Nishio ◽  
Tomoki Ebata ◽  
...  
HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e798 ◽  
Author(s):  
S. Nakahira ◽  
Y. Takeda ◽  
Y. Katsura ◽  
T. Irei ◽  
M. Inoue ◽  
...  

2020 ◽  
Vol 9 (3) ◽  
pp. 173-176
Author(s):  
Romi Dahal ◽  
Krishna Mohan Adhikari ◽  
Sumita Pradhan ◽  
Ramesh Singh Bhandari

Radical resection in a case of hilar cholangiocarcinoma is the only curative option. However resection in a hilar cholangiocarcinoma is a challenging procedure because of the low resectability rate. Only a few cases of hilar cholangiocarcinoma are operable because of the advanced nature of disease at presentation. Furthermore, the extent of surgery makes it a complicated process to attempt. We recently had a patient who underwent an open extended right hepatectomy and hepaticojejunostomy for a type IIIa hilar cholangiocarcinoma. The tumor was 20 mm in diameter and was located between the right hepatic duct and common hepatic duct. Radiological examination showed that the hepatic artery was not involved but the right portal vein was invaded by the tumor. CT volumetry was done and the future liver remnant was only 20% in the jaundiced patient. Preoperative drainage was done with percutaneous transhepatic biliary drainage from the left side. Portal vein embolization was done to augment future liver remnant to 30%. The patient underwent an extended right hepatectomy (right trisectionectomy combined with caudate lobectomy). The operation time was nearly 300 min, and the intraoperative blood loss was about 500 ml. However, in the postoperative period, the patient developed post hepatic liver failure which was managed successfully with conservative treatment. The postoperative hospital stay was 23 days. The final diagnosis was hilar cholangiocarcinoma with no nodal metastasis (pT2bN0M0) stage II (American Joint Committee on Cancer, AJCC).


Videoscopy ◽  
2011 ◽  
Vol 21 (6) ◽  
Author(s):  
Osamu Itano ◽  
Go Oshima ◽  
Shingo Maeda ◽  
Naokazu Chiba ◽  
Satoshi Aikou ◽  
...  

Videoscopy ◽  
2015 ◽  
Vol 25 (4) ◽  
Author(s):  
Shin Nakahira ◽  
Yutaka Takeda ◽  
Yoshiteru Katsura ◽  
Takeshi Kato ◽  
Nobutaka Hatanaka ◽  
...  

2005 ◽  
Vol 93 (1) ◽  
pp. 72-75 ◽  
Author(s):  
Mitsuo Miyazawa ◽  
Yasuko Toshimitsu ◽  
Takahiro Torii ◽  
Katsuya Okada ◽  
Isamu Koyama

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 200
Author(s):  
Salah Khayat ◽  
Gianluca Cassese ◽  
François Quenet ◽  
Christophe Cassinotto ◽  
Eric Assenat ◽  
...  

Colorectal liver metastases (CRLM) are the major cause of death in patients with colorectal cancer (CRC). The cornerstone treatment of CRLM is surgical resection. Post-operative morbidity and mortality are mainly linked to an inadequate future liver remnant (FLR). Nowadays preoperative portal vein embolization (PVE) is the most widely performed technique to increase the size of the future liver remnant (FLR) before major hepatectomies. One method recently proposed to increase the FLR is liver venous deprivation (LVD), but its oncological impact is still unknown. The aim of this study is to report first short- and long-term oncological outcomes after LVD in patients undergoing right (or extended right) hepatectomy for CRLM. Seventeen consecutive patients undergoing LVD between July 2015 and May 2020 before an (extended) right hepatectomy were retrospectively analyzed from an institutional database. Post-operative and follow-up data were analyzed and reported. Primary outcomes were 1-year and 3-year overall survival (OS) and hepatic recurrence (HR). Postoperative complications occurred in 8 patients (47%). No deaths occurred after surgery. HR occurred in 9 patients (52.9%). 1-year and 3-year OS were 87% (95% confidence interval [CI]: ±16%) and 60.3%, respectively (95% CI: ±23%). Median Disease-Free Survival (DFS) was 6 months (CI 95%: 4.7–7.2). With all the limitations of a retrospective study with a small sample size, LVD showed similar oncological outcomes compared to literature reports for Portal Vein Embolization (PVE).


Sign in / Sign up

Export Citation Format

Share Document